should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus Discontinue treatment in women at least 2 months before a planned pregnancy, owing to the long washout period for semaglutide Clinical Considerations Poorly controlled diabetes during pregnancy increases maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications Poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia-related Interaction Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase the risk of hypoglycemia
Concomitant potassium supplementation in the form of medication, potassium-containing salt substitute or potassium-enriched diets should also not be used
Sports technology and data are key to success, but come with legal risks
85,86 Recent literature supports the role of peptides in augmenting cell communication, reducing inflammation, and stimulating angiogenesis